{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-245206","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2025-10-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.848542+00:00","generated_at":"2026-05-17T03:01:51.003821+00:00","sec_items":["2.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Viridian expects ~$490.9M cash as of Sept 30, 2025; preliminary, unaudited","bullets":["Preliminary cash, equivalents, and marketable securities of ~$490.9M as of September 30, 2025.","Figure is unaudited and may materially differ from final Q3 2025 balance sheet upon close.","Full Q3 2025 financial results not yet finalized; no revenue or EPS guidance provided.","Disclosure intended to provide early liquidity visibility ahead of complete financial report."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-245206","json":"https://secwatch.observer/filing/0001193125-25-245206.json","markdown":"https://secwatch.observer/filing/0001193125-25-245206.md","text":"https://secwatch.observer/filing/0001193125-25-245206.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525245206/0001193125-25-245206-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525245206/d12120d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:01:51.003821+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}